PMID- 32736189
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20211002
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 87
DP  - 2020 Oct
TI  - Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and 
      inflammation in albumin-induced arthritis in temporomandibular joint of rats.
PG  - 106841
LID - S1567-5769(20)31464-8 [pii]
LID - 10.1016/j.intimp.2020.106841 [doi]
AB  - Rheumatoid arthritis (RA) is characterized by chronic inflammation of the 
      synovial tissue, joint dysfunction, and damage. Epoxyeicosatrienoic acids (EETs) 
      are endogenous anti-inflammatory compounds, which are quickly converted by the 
      soluble epoxide hydrolase (sEH) enzyme into a less active form with decreased 
      biological effects. The inhibition of the sEH enzyme has been used as a strategy 
      to lower nociception and inflammation. The goal of this study was to investigate 
      whether the peripheral treatment with the sEH enzyme inhibitor 1- 
      trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) could prevent 
      the hypernociception and inflammation in the albumin-induced arthritis model in 
      rats' temporomandibular joint (TMJ). After the induction of experimental 
      arthritis, animals were assessed for nociceptive behavior test, leukocyte 
      infiltration counts and histologic analysis, ELISA to quantify several cytokines 
      and Western blotting. The peripheral pretreatment with TPPU inhibited the 
      arthritis-induced TMJ hypernociception and leukocyte migration. Moreover, the 
      local concentrations of proinflammatory cytokines were diminished by TPPU, while 
      the anti-inflammatory cytokine interleukin-10 was up-regulated in the TMJ tissue. 
      Finally, TPPU significantly decreased protein expression of iNOS, while did not 
      alter the expression of MRC1. This study provides evidence that the peripheral 
      administration of TPPU reduces hypernociception and inflammation in TMJ 
      experimental arthritis.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Teixeira, Juliana Maia
AU  - Teixeira JM
AD  - Faculdade Sao Leopoldo Mandic, Instituto de Pesquisas Sao Leopoldo Mandic, 
      Laboratoy of Neuroimmune Interface of Pain Research, Campinas, SP, Brazil.
FAU - Abdalla, Henrique Ballassini
AU  - Abdalla HB
AD  - Faculdade Sao Leopoldo Mandic, Instituto de Pesquisas Sao Leopoldo Mandic, 
      Laboratoy of Neuroimmune Interface of Pain Research, Campinas, SP, Brazil.
FAU - Basting, Rosanna Tarkany
AU  - Basting RT
AD  - Faculdade Sao Leopoldo Mandic, Instituto de Pesquisas Sao Leopoldo Mandic, 
      Laboratoy of Neuroimmune Interface of Pain Research, Campinas, SP, Brazil.
FAU - Hammock, Bruce D
AU  - Hammock BD
AD  - Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, 
      University of California, Davis, CA, USA.
FAU - Napimoga, Marcelo Henrique
AU  - Napimoga MH
AD  - Faculdade Sao Leopoldo Mandic, Instituto de Pesquisas Sao Leopoldo Mandic, 
      Laboratoy of Neuroimmune Interface of Pain Research, Campinas, SP, Brazil.
FAU - Clemente-Napimoga, Juliana Trindade
AU  - Clemente-Napimoga JT
AD  - Faculdade Sao Leopoldo Mandic, Instituto de Pesquisas Sao Leopoldo Mandic, 
      Laboratoy of Neuroimmune Interface of Pain Research, Campinas, SP, Brazil. 
      Electronic address: juliana.napimoga@slmandic.edu.br.
LA  - eng
GR  - P42 ES004699/ES/NIEHS NIH HHS/United States
GR  - R35 ES030443/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20200728
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea)
RN  - 0 (Albumins)
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Piperidines)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, rat)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Albumins
MH  - Analgesics/pharmacology/*therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Arthritis, Experimental/*drug therapy/immunology/pathology
MH  - Cytokines/immunology
MH  - Epoxide Hydrolases/*antagonists & inhibitors
MH  - Male
MH  - Nitric Oxide Synthase Type II/immunology
MH  - Phenylurea Compounds/pharmacology/*therapeutic use
MH  - Piperidines/pharmacology/*therapeutic use
MH  - Rats, Wistar
MH  - Temporomandibular Joint/*drug effects/immunology/pathology
PMC - PMC8015648
MID - NIHMS1682214
OTO - NOTNLM
OT  - Hypernociception
OT  - Inflammation
OT  - Soluble epoxide hydrolase enzyme
OT  - TPPU
OT  - Temporomandibular joint
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/01 06:00
MHDA- 2021/05/28 06:00
PMCR- 2021/10/01
CRDT- 2020/08/01 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - S1567-5769(20)31464-8 [pii]
AID - 10.1016/j.intimp.2020.106841 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2020 Oct;87:106841. doi: 10.1016/j.intimp.2020.106841. Epub 
      2020 Jul 28.